TB-500
Thymosin Beta-4 Synthetic Fragment
A synthetic version of Thymosin Beta-4 studied in animal models for wound healing, tissue repair, and reduced inflammation.
Overview
TB-500 relates to Thymosin Beta-4, a peptide present in most cells. Preclinical research points to roles in actin regulation, angiogenesis, and cell migration to injury sites. As with BPC-157, human clinical evidence is limited and it is not an approved therapeutic. Regulatory update, September 2026: the FDA removed this peptide from Category 2 of the 503A bulk-drug list in April 2026, and on July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee voted to recommend it for compounding against the advice of FDA scientists, who found no adequate human data. The vote is advisory; nothing changes until FDA rulemaking, and vials sold 'for research' remain unapproved drugs.
Mechanism of action
Promotes actin polymerization, angiogenesis, and migration of repair cells to sites of injury in animal models.
Key studies & citations
- Review2010
Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide
Reviews the animal-model work (dermal, corneal, cardiac) that underpinned thymosin beta-4 clinical trials: reduced inflammatory cytokines, cell migration, angiogenesis and survival.
Annals of the New York Academy of Sciences - Animal2004
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
After coronary artery ligation in mice, thymosin beta-4 upregulated ILK/Akt, enhanced early myocyte survival and improved cardiac function.
Nature - Animal1999
Thymosin beta4 accelerates wound healing
In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at day 4 and up to 61% at day 7, with more collagen deposition and angiogenesis.
Journal of Investigative Dermatology - Review2026
July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
Official FDA meeting record: TB-500 (free base and acetate) was discussed on July 23, 2026 for possible inclusion on the 503A bulk drug substances list.
U.S. Food and Drug Administration
Frequently asked questions
Is TB-500 the same as Thymosin Beta-4?
TB-500 is a synthetic fragment related to Thymosin Beta-4. They are studied for similar repair-related effects but are not identical molecules.